

**ENDLESS
FRONTIER**

LABS

Mentor Roster

Life Sciences and Digital Health

**Arthur Klausner****Chief Mentor - Life Sciences**

Life Sciences Executive and Investor

An experienced life sciences executive and investor, Arthur Klausner currently serves as Executive Chairman of Concarlo Therapeutics (oncology) and is the former CEO of Goldilocks Therapeutics (nephrology), Gem Pharmaceuticals (oncology), and Jade Therapeutics (ophthalmology). He currently serves as a board member of Monopar Therapeutics, Beryl Therapeutics, and Gem Pharmaceuticals. Prior to his operating roles, Arthur spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures.

**Bob Schneider****Chief Mentor - Life Sciences**

Associate Dean and Professor, Radiation and Oncology, NYU Langone Health

Dr. Robert Schneider is the Albert B. Sabin Professor of Microbiology and Molecular Pathogenesis at NYU School of Medicine, associate director of the NYU Cancer Institute, director of Translational Cancer Research, and co-director of the Breast Cancer Research Program at NYU School of Medicine. He is also the Associate Dean of Biomedical Innovation and Commercialization, leading several science- and tech-focused efforts such as BioLabs@NYULangone. His team's research is focused on advanced breast cancer genetics, gene regulation by ionizing radiation, and the regulation of the inflammatory response in cytokine mRNAs connected to cancer development and progression.

**Kenneth Moch****Chief Mentor - Life Sciences**

President, Euclidean Life Science Advisors, LLC and Serial Biotech Entrepreneur

Ken has broad expertise building, financing and leading life science companies, having co-founded or served as President & CEO of six life sciences companies. Through these and numerous Board involvements, Ken has worked to develop new medicines against life threatening conditions including Alzheimer's and other neurodegenerative diseases, viral diseases, cardiovascular disease, diabetes, and cancer. Early in his career Ken pioneered the use of cord blood stem cells in transplantation therapy and launched the first cord blood storage bank. Ken started his career in biotech drug development as a co-founder and Vice President of The Liposome Company, which pioneered the use of lipid nanoparticles. He has also been a Managing Director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company, Inc.

Ken served for two decades on the Governing Board of the Biotechnology Innovation Organization, most recently focusing on bioethical issues as well as on the difficulties of developing new medicines for highly prevalent chronic diseases, and was the Chairman of BioNJ, helping to build the biotech infrastructure within New Jersey. He is a founding member of the Working Group on Compassionate Use and Pre-Approval Access at NYU, where he is also a Faculty Affiliate in the Department of Medical Ethics. His involvement in medical ethics was catalyzed by experiences documented in a Harvard Business School case study, 'Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix. Ken holds an A.B. in biochemistry with a minor in health policy from Princeton University and an MBA from Stanford University.

**Rana Al-Hallaq****Chief Mentor - Life Sciences**

Partner, Pfizer Ventures and Executive Director, Worldwide Business Development, Pfizer

Dr. Rana Al-Hallaq is Executive Director and Partner at Pfizer Ventures. Dr. Al-Hallaq has extensive experience in life science research and business development and leverages her preclinical, clinical, and business development experience to assess, invest in, and manage equity investments for Pfizer Ventures. Dr. Al-Hallaq has served as a business mentor through NYC's ELab program.

Adam Wollowick

Mentor - Digital Health

Senior Director of Business Development, Stryker Trauma and Extremities

Dr. Wollowick currently serves as Senior Director of Business Development at Stryker Trauma & Extremities and focuses on mergers and acquisitions. From 2014-2023, Adam was Senior Director of Business Development, Market Insights & Strategy for Stryker Spine in Allendale, NJ. He is currently an advisor to Precision Life Science Partners, a medtech consulting firm, and serves on the Scientific Advisory Board of Matricelf, an Israeli biotech company. Prior to joining Stryker, Adam worked as an attending surgeon in the Department of Orthopaedic Surgery at Montefiore Medical Center, Bronx, NY and specialized in adult and pediatric spine surgery. He held the title of Assistant Professor of Orthopaedic Surgery at the Albert Einstein College of Medicine, Bronx, NY.



Alan Harris

Mentor - Life Sciences, Deep Tech

Physician-Scientist Entrepreneur and Pharmaceutical Executive

Alan Harris, MD, PhD, FACP, FRCP is a Physician-Scientist Entrepreneur and Pharmaceutical Executive at Novartis, Schering-Plough- Merck, Pfizer, NPS, Radius, and Recordati with 30 years of success across a broad range of therapeutic areas from rare disease treatments to widely prescribed medicines (Zetia, Claritin, Nasonex). He has worked with Novartis, Schering-Plough- Merck, Pfizer, NPS, Radius, and Recordati. He completed the top-performing biotech IPO in 2014 as Chief Medical Officer (CMO) at Radius Health. At Novartis, he led the worldwide clinical development and approval of the first somatostatin analog, octreotide (Sandostatin®, Novartis), for the treatment of malignant Neuroendocrine Tumors (NETs) and acromegaly generating peak sales of \$1.6B/year. He was also involved in the development of the first somatostatin peptide-based diagnostic imaging agent (Octreoscan®) for NETS and the Peptide Radionuclide Radiotherapy (PRRT) agent, Lutathera®, while at Biosyntherma acquired by AAA that was sold to Novartis for \$3.9B. Alan has expertise in developing cancer biomarkers in hormone-related cancers. He oversaw as CMO the FDA approval of the bone forming agent Tymlos for the treatment of postmenopausal osteoporosis. He spearheaded, as CMO, at Recordati Rare Diseases, the \$390M purchase of two endocrine drugs from Novartis. He founded two peptide therapeutics companies in Switzerland and the US and sold one to Amryt Pharmaceuticals/Chiesi.

Alan was awarded an MD from Strasbourg University School of Medicine, France, and a Ph.D. in Endocrinology University of Rotterdam. He was previously an associate Professor of Medicine at UCLA Cedars Sinai Medical Center and is currently adjunct Professor of Medicine in the division of endocrinology at NYU Grossman School of Medicine.



Alan Roemer

Mentor - Life Sciences

Board of Directors, Multiple Biotechnology Companies

Alan S. Roemer, MBA, MPH is a life sciences entrepreneur and board member who has launched three multi-billion-dollar biotechnology companies resulting in 9 new drug approvals, raised over \$1.75 billion in private and public capital, consummated five IPOs, and executed numerous business development transactions. He currently serves as chairman of the Board of Directors of IN8bio and UTILITY Therapeutics; member of the Board of Directors of NexImmune and bit.bio; trustee and treasurer of the Helene Fuld College of Nursing; senior advisor of Biologic Design; and strategic partner of Forty51 Ventures. Mr. Roemer received a BSBA from Georgetown University and MBA and MPH degrees from Emory University's Goizueta Business School and Rollins School of Public Health.



Alex Schubert

Mentor - Life Sciences

Partner, SciFounders

I am a scientist by training, completed my PhD at the University of Cambridge, and later joined Genentech's Research and Early Development department. I started SciFounders with other scientists and biotech founders to help more technical founders start and run their own companies. We invest from pre-seed to Series A.

If you are working on an impactful technology and are thinking about starting your own company, I would love to connect.



Andrei Vrabie

Mentor - Digital Health, Digital Tech

GC & COO, Parameter Ventures

Andrei is the Chief Operating Officer and general counsel at Parameter Ventures, a New York venture capital firm purpose-built to help enterprise software pioneers create category-defining products.

Andrei brings over 15 years of experience advising financial institutions on commercial, regulatory, transactional, and other matters. Complementing his legal experience, Andrei has also advised corporations on business strategy at Monitor Deloitte and is an active investor in startups.

Andrei earned a JD from Columbia Law School and BSc in economics and international business from New York University, Stern School of Business.



Andrew Hamilton

Mentor - Life Sciences

President Emeritus, New York University

Andrew Hamilton served as the 16th President of NYU from January 2016 to June 2023. In July 2023, he was succeeded by Linda G. Mills.

A noted chemist and Fellow of the Royal Society who came to NYU's presidency from the vice chancellorship of the University of Oxford, Andrew Hamilton skillfully led NYU through the COVID-19's challenges, ensuring fulfillment of the University's scholarly mission, advancing its academic momentum, and steering NYU past the pandemic's most serious straits. During his presidency, applications for first-year admission came to exceed well over 100,000, leading to NYU's most selective and diverse freshman classes. He slowed the growth of tuition, greatly enhanced financial aid, and enrolled the first entering classes for which NYU met demonstrated need. Under his leadership, NYU attained all-time highs in both national and international stature, surpassed \$1 billion in research spending, appointed its first chief diversity officer, received almost \$5.5 billion in philanthropic funding, exercised financial stewardship that resulted in budgetary surpluses each year, and opened major new academic facilities in Manhattan, Brooklyn, and Shanghai.



Andrew Koopman

Mentor - Life Sciences

President, NextStage Bioconsulting

Experienced, creative business development expert, entrepreneur, C-level executive, and scientist working with investors, entrepreneurs, academia, industry partners, and life science incubators to commercialize nascent technologies to build successful ventures. Background in strategic and IP management, due diligence, investment, technology transfer, product development, and manufacturing, through positions in small biotech, big pharma, Wall Street, and NFP's.



Andy Feldstein

Mentor - Digital Health, Digital + Deep Tech

President, ViaSpectrum

Andy Feldstein is an entrepreneur with over 30 years experience in the defense and wireless industry. He spent his career developing innovative products for wireless and networking application.

Andy was co-founder and CEO of Innovative Concepts, Inc., a product development company servicing all the US armed forces, and many allied forces. In his capacity as CEO, he has developed a very strong international business that sold products to companies and government agencies in Europe, Asia, and Australia. After Innovative Concepts, Inc., was sold to Herley Industries; Andy became Herley's Chief Technology Officer. In addition to performing the normal CTO activities, he also supported and managed M&A endeavors. Andy was also the president of T2I, Inc., a manufacturer of tactical communication systems.

Andy provides management consulting services to large and small companies on various strategic initiatives and new product market penetration. In addition, he is an active investor in a number of startups focusing on the healthcare industry.

Andy served on board of directors and board of advisors of a number of not-for-profit association established to develop futuristic standards for state of the art communications and networking systems, as well as for profit corporations. He has been a member of the following boards, Innovative Concepts, Inc., T2I, Inc., Wireless and Innovation Forum (formally SDR Forum), DirecNet Forum, and he Currently serves on the board of SDI, Inc.

He has a DSc in engineering from George Washington University and BSEE degree from Penn State University.



Anjali Ganguli

Chief Business Officer, Syndax Pharmaceuticals

Mentor - Life Sciences

Anjali Ganguli is currently the Chief Business Officer of Corporate Development at Syndax Pharmaceuticals NYC. At Syndax, Anjali leads business development, investor relations, alliance management, and pre-commercial efforts. Anjali has spent over 12 years facilitating health care businesses through both research and consulting. She earned a B.S. at the University of Chicago, a Ph.D. in Medicinal Chemistry from the University of Michigan, and conducted her post-doctoral research in biochemistry at the University of California Berkley.



Anthony Curro

Board Chair, Xylyx Bio Inc.; Curro Consulting

Mentor - Life Sciences

Anthony Curro has over 35 years of senior executive experience in life sciences, technology, and finance, with demonstrated expertise in business strategy, market and risk assessment, global distribution, and the commercialization of novel medical devices and biotechnologies. He served as Vice President and General Manager of Australia-based Compumedics, heading up their North American business unit, and as a Director at medical device powerhouse Guidant (Boston Scientific), where he successfully grew the company's portfolio of cardiovascular products. He also served as CEO at Immplacate, a cell therapy company, and CEO of Spruce Technology, where he led the firm through an extended period of high growth and expansion. Anthony holds an MBA from Columbia University, serves on multiple corporate boards, and has an established network that extends through the Americas, Europe, and the Pacific Rim.



Arda Ural

Americas Leader for Life Sciences Sector, Ernst & Young (EY)

Mentor - Life Sciences

Arda Ural is the Americas Life Sciences leader of Ernst & Young (EY), a \$55B professional services firm. For the last four years, he has been leading this complex business comprising of strategy, consulting, M&A, technology, tax and assurance capabilities to surpass \$2.0B in revenue with consistent profitable growth. Arda has a proven operational track record in pharma, biotech, med tech and pharmaceutical services industries with accomplishments in general management, corporate strategy, commercialization, product development, mergers, divestitures and acquisitions stretching over 30 years both in the US and globally.

Prior to joining EY, Arda was a Managing Director at Accenture, where he led the firm's Life Sciences M&A Practice. Earlier, Arda worked as a VP of Strategic Marketing and a BU Leader at Becton Dickinson, a Fortune 500 medical technology company. He also served as the SVP Marketing & Sales for a start-up biotechnology company EyeTech which went public before getting acquired by Astellas. Arda started his career with Pfizer in Istanbul, Turkey and subsequently relocated to its New York Headquarters where he held leadership roles for ten years in commercialization and new product development, such as having launched Viagra worldwide and led the \$2B Celebrex business in the US to high growth.

He is an inclusive talent leader, who built diverse and high-performing teams that achieved stretched goals together. His leadership style is leading from the front to make a significant impact on the businesses for which he is accountable. He is an engaged coach who over the course of his career inspired and developed his team members to further leadership roles across the industry. Importantly, he has a track record of leveraging emerging technologies to create differentiated growth opportunities.

Arda has an engaged network in the industry with leadership roles across several biopharmaceutical associations. In 2024 he was recognized as a PharmaVoice 100 Standup Leader thanks to his impact on the industry. Arda was also honored as a "Global Turk par Excellence" by AmCham and Heidrich & Struggles in 2022. Specifically, he is the Chair of BioNJ C-Suite Summit and serves as a judge at the BioPartnering Program. He is also a member of BIO Business Development and Finance Committee, Advisory Board Member of NJIT (New Jersey Institute of Technology) Biomedical Engineering Committee, a Member of In Vivo Editorial Advisory Board and a Forbes Magazine Contributor and Finance Council Member. He serves as EY's executive liaison to Carnegie Hall in New York City and executive sponsor for Liberty Science Center, SciTech City Initiative. He also was a board of director for Brooklyn Conservatory of Music serving underprivileged communities.

He is a frequent keynote speaker, and his thought leadership can be followed at his LinkedIn platform in addition to his professional profile at EY.com.

Arda earned his PhD in Finance and an MBA from Marmara University (top of his class) whereas he completed his MSc (top of his class) in Material Science and BSc in Mechanical Engineering from Boğaziçi University. He speaks German and Turkish. Arda and his wife Chala live in New Jersey and have two children.



Ashwath Kumar

Mentor - Life Sciences, Digital Health

Computational Biologist, Parse Biosciences

Ashwath is an accomplished computational biologist with extensive experience in bioinformatics and data analysis. He currently co-directs computational efforts at Parse Biosciences, a startup specializing in scalable single-cell sequencing products, where he has significantly contributed to developing robust algorithms. Ashwath's career includes experience at pharmaceutical companies and research labs, leading computational projects for drug discovery at various phases. He also serves as an industry expert and mentor with the SPARK program at Stanford. Ashwath's expertise lies in establishing and refining computational pipelines, machine learning frameworks, and data analysis protocols. He holds a Bachelor's in Biotechnology from India, and both a Master's and a PhD in Bioinformatics from the Georgia Institute of Technology.



Avi Rosenbaum

Mentor - Life Sciences, Digital Health

Founder, Advisors.bio

Avi advises venture capital firms and startups developing novel therapeutics, diagnostics, research tools, and SaaS solutions for the biotech industry. Previously, he spent 7 years at Ion Torrent Systems (acquired by Thermo Fisher Scientific) where his R&D team developed over ten products. Avi has a Ph.D. in Genetics from George Church at Harvard University, where his research focused on technologies for sequencing and interpreting personal genomes.



Bharat Tewarie

Mentor - Life Sciences, Digital Health

Founder, Boston BioPharma Consultants / Board of Directors, Alveo Technologies / CEO and Chair Board Of Directors, ViroCarb

Dr. Bharat Tewarie is a C-suite executive with extensive experience in the BioPharma, Medical Devices and Digital Health industry as CEO of early-stage BioPharma and digital health companies and Chief Marketing Officer at a public BioPharma company.

After his training as medical doctor (MD) with a MBA, he has held roles with increasing commercial responsibilities in Europe and USA. These were at BioPharma companies such as Boehringer Ingelheim, Roche, Serono International, EMD Serono, Merck Serono, UCB and emerging biotech & digital health companies.

From 2015-2020, Bharat worked as the Executive Vice President & Chief Marketing Officer and member of the Executive Committee of UCB. In January 2020, he founded Boston BioPharma Consultants advising executives of BioPharma and medical device companies about commercial topics.

Since January 2021 he is the CEO and Chairman of an early-stage antiviral development company ViroCarb Inc, and an independent Board director at Aveta Biomics.



Bruce Cronstein

Professor, Medicine, NYU Langone Health

Mentor - Life Sciences

Dr. Bruce Cronstein received his bachelor's degree from Lake Forest College and his medical degree from the University of Cincinnati College of Medicine. He completed his residency in Pathology at the NYU Medical Center and a residency in Internal Medicine at Lenox Hill Hospital. Dr. Cronstein completed his training in rheumatology at NYU Medical Center and, supported by a Fellowship Award from the Arthritis Foundation, continued his research training. From 1985-1990 Dr. Cronstein was a recipient of a Clinical Investigator Award from the National Institutes of Health and in 1988 Dr. Cronstein was awarded the Irene Duggan Arthritis Investigator Award. In 1989 Dr. Cronstein was a recipient of a Whitehead Presidential Fellowship. Dr. Cronstein was also named a Postdoctoral Fellowship Program Research Hero of the Arthritis Foundation. Dr. Cronstein is the 2013 recipient of the Lee C. Howley, Sr. Prize for Arthritis Research from the Arthritis Foundation, the 2017 recipient of the John Vane Medal of the William Harvey Research Institute and the 2019 recipient Distinguished Basic Scientist Award from the American College of Rheumatology. Dr. Cronstein has previously served as the Director of Rheumatology and Director of the Arthritis Clinic at Bellevue Hospital. From 1988 to 1991, he was a member of the New York Chapter Arthritis Foundation Grant Review Committee and from 1992 to 1994 served as Chairman of the Committee. Dr. Cronstein is also a past President of the New York Rheumatism Association. Dr. Cronstein has served on the Arthritis, Connective Tissue and Skin Diseases Study Section of the NIH from 2001-2004 and chaired the committee from 2004-2006 and has served on numerous other grant review committees. He is the founding Director of the master's in Clinical Investigation Training Program at NYU School of Medicine where he is the Director of the Clinical and Translational Science Institute. Dr. Cronstein has served on numerous committees at NYU School of Medicine as well as serving on numerous committees of the American College of Rheumatology.



Bruce Zetter

Charles Nowiszewski Professor of Cancer Biology, Harvard Medical School

Scientific Mentor - Life Sciences

Bruce Zetter is the Charles Nowiszewski Professor of Cancer Biology at Harvard Medical School. His research focuses on extending the lives of cancer patients, and he has devoted his career to studying how cancer evolves, spreads, and causes patient harm. His work has revealed new biomarkers to predict cancer outcomes and new treatments for late-stage cancers. Dr. Zetter has served as a consultant or board member to 40+ biotechnology and pharmaceutical companies and also serves as an advisor to venture and investment firms. He has won numerous awards for his work in cancer research and has received three awards from Harvard Medical School for excellence in teaching, mentoring, and leadership. He is a frequent advisor to young scientists and entrepreneurs starting companies in biotechnology. Prior to Harvard, Dr. Zetter received a B.A. in Anthropology from Brandeis University and a Ph.D. from the University of Rhode Island. He currently conducts research at Boston Children's Hospital where he has served as Vice President of Research and Chief Scientific Officer.



Carmen Kerschbaum

Senior Executive / CFO / COO; Life Sciences Executive & Investor

Mentor - Life Sciences, Digital Health

Carmen is a recognized leader and advisor in finance, operations, digital, business development and strategic innovation across global life sciences and automotive industry. With over 20 years of finance and operational expertise, including more than 15 years in the healthcare sector, she brings a unique perspective on the needs of patients, the role of investors, and the rapidly evolving healthcare landscape.

Most recently, Carmen was the SVP Finance for Pfizer Worldwide Research and Development, Oncology Division (CFO) and Business Innovation (incl. M&A and Portfolio/Strategy Finance). In this role, she prioritized internal and external investments for Pfizer's R&D pipeline, led business development activities, fostered ecosystem relationships, and oversaw the creation of a new Oncology division including the integration of Seagen. Prior to Pfizer, Carmen held global finance, strategy, partnerships, and operational leadership roles at Roche / Genentech.

Before joining Roche/Genentech, she served as Corporate Controller for Behr America, where she was responsible for all aspects of financial planning, business finance, analytics and management.

With fluency in multiple languages, she has a global mindset, strong understanding of international operations and a proven track record of effectively building and leading diverse cross-functional teams.

Carmen earned a M.B.A. and Process Engineering degree from the University of Stuttgart, Germany.



Casey Perley

Mentor - Life Sciences

Director, Army Applications Laboratory

Dr. Perley is a biodefense scientist and leader who is committed to accelerating technology into the DOD and the hands of the warfighter. She holds a B.S. in Molecular Biophysics and Biochemistry from Yale University, a Ph.D. in Molecular Genetics and Microbiology from Duke University, and spent four years as a post-doctoral fellow in the Virology Section of the US Army Medical Research Institute of Infectious Diseases. She has over a decade of experience studying deadly pathogens in high containment facilities (i.e. Biosafety level 3 and 4) that threaten U.S. Soldiers and public health. Since leaving the bench, Dr. Perley has focused on harnessing our national innovation base for Army modernization. She drove the establishment of AAL's Special Program Award for Required Technology Needs (SPARTN) - a new business model that reduced bureaucracy, and made it easier for small businesses to pivot their technology to solving Army problems.



Chris Maher

Mentor - Digital Health

Founder & General Partner, Samaritan Partners

Chris Maher is the Founder and General Partner at Samaritan Partners, a public benefit impact venture capital fund. Samaritan is striving to create a more inclusive and accessible world by accelerating capital investment and partnership in early-stage, for-profit companies serving the disability community. Present portfolio companies include Be My Eyes, Wheel the World, Sign-Speak, and Making Space.

Prior to founding Samaritan, Chris spent 25 years as an operator and CEO of a variety of companies across a broad cross-section of the digital economy including SaaS, AdTech, MarTech, consumer research, and data businesses. Over the years, Chris has developed extensive operational expertise across sales, marketing, people management, product, finance, and strategic planning. In addition, he has considerable experience in raising capital and M&A work.

Previously, Chris spent a decade coaching Division I college basketball at several schools including Boston College, Dartmouth College, and Brown University. A coach at heart, Chris has spent the past 30+ years building, mentoring, and leading teams.

The impetus for starting Samaritan Partners is anchored in Chris' broad entrepreneurial background and a passionate desire to help those in need or that are facing adversity. Chris and his wife have raised two beautiful daughters, both of whom live with physical or developmental disabilities. This led the family to get deeply involved with their local school district and community organizations that offer services to enhance the lives of children with disabilities. They have also supported several other family members and close friends navigating life-altering challenges and therefore have dedicated time to raising money and volunteering for various nonprofit organizations.



Christopher McKelvy

Mentor - Digital Health

Managing Partner, K. Ventures

Christopher is the founder and managing partner of K. Ventures, an early stage venture capital firm investing in the best technology startups in the world that transform lives for people with disabilities, their caregivers and loved ones. Prior to K. Ventures, Christopher was an early employee at Oculus VR, which sold to Meta for \$2.1B. He is also an Army Veteran and served as the Vice Chairman of the Joseph P. Kennedy Jr. Foundation.



Claire Leurent

Mentor - Life Sciences

Strategic Investor in Biotech & Healthcare

Claire Leurent PhD MBA is a venture capital investor with operational experience in leading drug development from scientific discovery to registration studies enabling regulatory approval applications. She is passionate about science and people and highly motivated by the opportunity to deploy transformative technologies and business models to generate progress in the community.

Claire earned her PhD in molecular and cellular biology at the Institute of Genetics, Molecular and Cellular Biology (IGBMC) in Strasbourg Illkirch-Graffenstaden, France in 2002. She then worked in drug development in several capacities for 14 years. She started as a Project Manager in a First in Human clinical center at Forenap Pharma in Rouffach. She was then hired by Wyeth Pharmaceutical in Paris as a Senior Clinical Scientist to support global phase 3 registration trials, NDA dossier submission and new product launch for a variety of programs in Women's health and Neuroscience. In 2010, she relocated to the United States to join Pfizer Research and Development in Groton CT then in Cambridge MA, where she led teams in designing and conducting clinical plans from First in Human to Proof of Concept studies for small molecules, biologics, and biomarker technologies. Over the years, she developed a passion for the business aspects of innovation. She became a standing member of the Portfolio Enhancement team responsible for screening external opportunities for business development and did an internship with Pfizer's Strategic Investment in 2015.

Claire obtained her MBA from MIT Sloan in June 2016 and then pivoted to corporate venture investment as a way to scale up and diversify the breadth of her technological reach and gain prime experience in virtually all stages of investments (Seed to PIPE/SPAC) in established corporate venture funds. She joined Samsung Venture America, the investment entity serving Samsung conglomerate, in 2017 with a focus on deploying capital in Life Science, Health Economics, and Connected Health sectors. In 2019, she joined JJDC, the investment team serving Johnson & Johnson, with a focus on pharmaceutical areas across neurosciences, oncology, infectious diseases and vaccines, cardiovascular, renal diseases, ophthalmology, immunology, inflammation, and modalities encompassing small/large molecules, cell/gene therapy, RNA and RNA-targeting, AI/ML, and quantum computing.

Claire is an active contributor to the innovation ecosystem and has been mentoring entrepreneurs and students in various capacities. In June 2023, she joined the National Institutes of Health as an Entrepreneur in Residence.



Danny Levner

Mentor - Life Sciences, Digital Health

Co-Founder, Chief Technology Officer, Board Member, Emulate, Inc.

Co-Founder and Chairman, Sight Diagnostics

Dr. Daniel Levner is a Co-Founder and Chief Technology Officer at Emulate, Inc., a life-sciences company that creates advanced biological models of the human body for understanding how diseases, medicines and chemicals affect human health. The company's products ' Organ-Chips ' have found diverse use in the pharmaceutical industry in the assessment of drug efficacy, safety and mechanism of action, with the promise of decreasing clinical-trial failure rates, reining in the costs of drug development and reducing the dependence on animal testing. Dr. Levner is also a Co-Founder of Sight Diagnostics, which produces compact blood analyzers that enable patients to receive their results in minutes instead of waiting days. Sight has accomplished this using deep expertise in AI combined with a unique new method for 'digitizing blood'. Dr. Levner was formerly a Senior Staff Scientist at Harvard University's Wyss Institute for Biologically Inspired Engineering, where he led a multidisciplinary engineering team that developed foundational Organs-on-Chip technology. Prior to the Wyss Institute, Dr. Levner worked with world-renowned Harvard geneticist Prof. George Church in programs related to medical diagnostics, DNA/RNA sequencing and multiplexed biological sample analysis. Dr. Levner received his Ph.D. in Electrical Engineering from Stanford University as well as an M.S. in Aeronautics and Astronautics, also from Stanford. He has authored numerous publications and more than 70 issued and pending US patents.



David Fenyo

Mentor - Life Sciences

Professor, Computational Biology, NYU Langone Health

Dr. David Fenyo is currently a Professor in the Department of Biochemistry, Co-Director for the Biomedical Informatics Core at the Clinical and Translational Science Institute. He is also participating in the programs of the NCI's Clinical Proteomic Tumor Analysis Consortium and the National Center for Dynamic Interactome Research. Dr. Fenyo's research focuses on providing a detailed understanding of the dynamics of cellular processes. His efforts to integrate data from multiple technologies ' including mass spectrometry, sequencing, and microscopy ' have provided a wide array of powerful tools for discovering and verifying biomarkers and therapeutic targets in cancer.



David Nierengarten

Mentor - Life Sciences

Research Analyst and Managing Director, Wedbush Securities

I have 20 years of experience in the 'financial' side of the biotech industry, as an investor, in operations and in sell side equity research. I enjoy working with development stage biotechnology companies and investors.



Dennis Hillen

Mentor - Digital Health

Former SVP, Insurance Strategy, Oscar Health

Dennis Hillen is currently the Senior Vice President, Insurance Strategy for Oscar Health, leading market development, product development, and strategic partnerships. Prior to this role, Dennis held market-level growth and P&L responsibility throughout Oscar's transition from a pre-IPO start-up to a sustainable publicly traded company.

Before joining Oscar, Dennis served in a series of successive roles at Humana ultimately leading Innovation and Enterprise Transformation efforts focused on value-based care and simplifying provider and healthcare consumer experiences, including the development and successful spin-out of a VC-backed startup



Deren Koseoglu

Mentor - Life Sciences

Vice President of Global Accounts, eMolecules

With a successful career in biotechnology and sales, I am a customer-focused sales leader well-versed in the pharmaceutical, biotechnology, and software industries. My journey has involved early stage R&D and manufacturing, allowing me to understand various manufacturing processes and possess an analytical and chemical oriented background. I excel in building strong customer relationships, exceeding sales targets, and negotiating complex deals, showcasing my expertise in locating and closing new business.

In my current role as Vice President of Global Accounts at eMolecules, I oversee a significant portfolio of commercial pharmaceutical accounts globally. Directing a team, I drive strategic initiatives to exceed revenue targets and foster partnerships with key stakeholders within pharmaceutical accounts. I have built the GTM strategy for our biotech product and initiative and lead marketing efforts in that regard.

Previously, as Director of Sales at Schrödinger, a leading life science software firm, I managed a significant portfolio of commercial pharmaceutical and biotech accounts and led a team of account managers with a quota exceeding \$5M. My tenure saw the establishment of strategic partnerships and significant revenue growth. Earlier roles, including Senior Account Manager at Schrödinger and Marketing Account Manager at Kaneka North America, saw consistent increases in sales, establishment of new business, and formation of key service partnerships within the biotechnology and CASE sectors.

My educational background includes a Master of Business Administration (MBA) with a focus on Marketing/Go-to-Market Strategy from Rice University and a Bachelor of Science in Chemistry from Texas A&M University.

Lastly, I now operate my own consulting firm offering business development, marketing, and GTM strategies for biotech and software firms.



Devin Mann

Mentor - Digital Tech

Director, HiBRID Lab, NYU Langone

Dr. Mann is the Director of NYU Grossman School of Medicine's Healthcare Innovation Bridging Research, Informatics, & Design (HiBRID) Lab, where he leads a hybrid program of research and operational innovation focused on enhancing healthcare delivery using novel technologies. His research seeks to develop and evaluate approaches to tighten the connection between health at home and in the office, using mobile technologies improve communication, deploy AI to support high quality care and optimize the electronic health record to promote evidence-based care while reducing clinician burden. He also directs NYU Langone's FuturePractice Lab, an internal technology innovation team of innovation managers, UX designers and technologists to accelerate the pace of digital health innovation exploration, development and deployment across the health system, and serves as the Strategic Director of Digital Health Innovation within the MCIT Department of Health Informatics at NYU Langone Health, an enterprise senior leadership role at the intersection of innovation and operations.



Doron Sagman

Mentor - Digital Health

President, Arel Biopharma Consulting Inc.

Doron Sagman is an MD/psychiatrist, venture capitalist, and R&D Life Sciences consultant with executive leadership experience in the biotech/pharmaceutical industry. As Vice President, R&D/Medical Affairs and Sr. Medical Director at Eli Lilly Canada, he led the medical, clinical and regulatory affairs divisions across a broad therapeutic span, including neuroscience/neurodegeneration, immunology, oncology, and diabetes, through multiple launches. As Chief Medical Officer at Mind Cure Health, he oversaw the early phase psychedelic R&D clinical development program and strategy. He is currently President of Arel Biopharma Consulting Inc., working with leading biotech firms and seed-stage companies. He is a Venture Partner at Treasure Coast Ventures, an investor/Life Science Advisor with K2X Technology and Life Science Inc., and a member of Mid Atlantic Bio Angels and Keiretsu Forum, with an overall focus on Life Sciences, MedTech, and Digital Health. Doron is a published author and psychiatrist with decades of inpatient and outpatient clinical experience centered on mood/anxiety disorders and ADHD, in both community and academic settings. He earned his BA from McGill University, an MD from the University of Calgary, and completed his psychiatric training at the University of Toronto.



Elcin Zan

Mentor - Life Sciences

Chair, Nuclear Medicine, Cleveland Clinic

Elcin Zan, MD, is the Chair of Nuclear Medicine at the Cleveland Clinic. Elcin is passionate about transforming the standard of care via scaling up early patient access to novel therapies, aiming to meaningfully improve patients' quality and quantity of life. She has embraced Theranostics approach, utilizing bio-identical molecules for both imaging and therapy by switching the type of radiation payload delivered to target cells in diseases such as cancer, endometriosis and chronic pain syndromes. Elcin has served as a medical consultant in the pharmaceutical, biotechnology and medical device companies. Elcin completed medical school in Ankara, Turkey followed by residency and fellowship training at the Johns Hopkins Hospital, Baltimore.



Eric Tan

Mentor - Life Sciences, Deep Tech, Digital Health

Partner, Blackwood Healthcare Breakthroughs

I am a scientist an engineer by training, specializing in medical devices, diagnostics, DNA & RNA replication and nanofabrication. I have spent 10 years in the medical device industry, assessing technologies from an early stage and taking them through the development process, including FDA approval and commercialization.



Gill Sawhney

Mentor - Life Sciences, Digital Health

Senior Life Sciences Investment Banker/Consultant

Gill is an investment and merchant banking professional with over 25 years of experience building and leading healthcare practices for premier investment banking firms. He has executed complex financial transactions and helped shape his clients' growth strategies to transform a broad range of life sciences and healthcare organizations. He provides counsel to C-suite executives, venture capital and private equity firms, specialty life sciences investors, and boards of directors. Over the course of his investment banking career, Gill has closed over 115 advisory and financing transactions with values ranging from \$25 million to \$1.5 billion. Gill most recently advised biopharmaceutical and other life sciences companies on strategy, corporate development and capital raising in therapeutic areas including oncology, rare disease and inflammation, among others. Gill's senior-level corporate finance and investment banking experience includes positions as managing director, global coordinator and sector head at ING Barings; partner and co-head of healthcare at Thomas Weisel Partners; co-head of healthcare and managing director at Morgan Joseph; and managing director at Cantor Fitzgerald. He earned his bachelor's in Economics from the University of Pennsylvania.



Gopal Gopalakrishnan

Co-Founder, Concerto.ai

Mentor - Digital Tech, Digital Health

Dr. P. (Gopal) Gopalakrishnan is an experienced technology leader, currently working with companies of various sizes to guide their strategy and technology directions. He is an accomplished technology executive who has successfully led product innovations, research, and technology strategy over the course of a distinguished career. He was formerly the Vice President, Corporate Technology, IBM Corporation, Armonk, NY. He is an early pioneer of AI and machine learning, having started his research career in speech recognition, natural language and conversational systems. He is the co-founder of a conversational AI company and is an advisor for several other startup companies in AI. He has published in many peer reviewed conferences and journals and has co-authored over twenty patents. Dr. Gopalakrishnan received his Ph.D. degree in Computer Science from the University of Maryland, College Park, where he has been inducted into the Alumni Hall of Fame.



Hernando Bunuan

Founder & Managing Partner, Z2Sixty Ventures

Mentor - Deep Tech, Digital Health

Hernando Bunuan is the Founder and Managing Partner of Z2Sixty Ventures, a US venture capital firm focused on pre-seed to Series A investments. He has over 20 years experience spanning investing (venture capital, angel and public equities) and investment banking (M&A and capital raising) in the US and Europe. He initially trained as a public accountant. Hernando has an MBA from Chicago Booth and Bachelor's from Washington University. He is a member of the National Association of Corporate Directors and is NACD Directorship Certified.



Howard Kivell

Former Urologic Surgeon, Integrated Medical Professionals, PLLC

Mentor - Digital Health

Dr. Kivell recently retired from the practice of urologic surgery. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons. He had admitting and operating privileges at New York Presbyterian (Cornell) and Montefiore/Einstein Hospitals. Dr Kivell received his BA from Cornell University, his MD from Thomas Jefferson University and his MBA (Finance) from the Stern School of Business (NYU). When he retired after over thirty years in practice he was a member of the second largest urology group in the country which was then sold to private equity investors. When he was practicing, he had special interests in the early detection and treatment of genito-urinary tumors, the minimally invasive treatment of benign conditions of the prostate and urinary stone disease.



Hyuk-Jeen Suh

General Partner, SkyRiver Ventures

Mentor - Deep Tech, Digital Tech, Digital Health

Hyuk-Jeen Suh is the General Partner of SkyRiver Ventures, a deep tech and digital health focused cross-border venture capital fund investing in frontier technologies. He brings 25 years of experience in the consumer electronics, biotech, finance and semiconductor industries.

Prior to SkyRiver Ventures, Hyuk-Jeen created and was the head of Samsung Ventures America east coast office. Before joining Samsung, he worked at J.P. Morgan investment banking in the Technology, Media, and Telecom group. Prior to J.P. Morgan, he was the global senior business development and marketing manager at MEMSIC, a semiconductor startup. He led the global marketing strategy which contributed to the successful IPO of the company. Before MEMSIC, Hyuk-Jeen was a senior research engineer at Sequenom, a biotech startup, where he designed DNA biochips. He began his career at Intel Corporation as a process engineer, leading yield improvement projects and contributing to the highest yield in Intel's history at the time for the Pentium microprocessor.

Hyuk-Jeen earned his Ph.D. in electrical engineering from University of Illinois at Urbana-Champaign. He earned his MBA from Yale School of Management. He holds a BS in mechanical engineering, BA in economics, and ME in electrical engineering, all from Cornell University.



Ian Greenberg

Mentor - Life Sciences

VP Business Development / Corporate Development, GSK

Ian Greenberg has 18+ years successfully leading complex transactions – acquisitions, licensing, & partnerships – buy/sell side

Broad Industry experience: cancer drug discovery (Merck), sales (Lilly), deal finance (BMS), transactions/search & evaluation (BMS), Transactions (GSK)

Proven leadership: large diverse cross-functional teams, direct reports, external advisors, & C-Level executives



James Beem

Mentor - Digital Health

Vice President, Socially Determined

James Beem, MHA, MHIIM, FACHE, is a distinguished healthcare executive with extensive experience across various facets of the industry. He holds a Master of Health Administration from the University of Kentucky and a Master of Health Informatics and Information Management from the University of Tennessee Health Science Center, combining strategic leadership with technical expertise in his approach to healthcare innovation.

Throughout his career, James has held senior leadership roles at renowned organizations, including Humana, Walgreens, Forsta/Press Ganey, J.D. Power, and IBM Watson Health. In these positions, he has been instrumental in driving innovation, fostering growth, and shaping the future of healthcare delivery.

James's influence extends beyond corporate leadership. He serves on several boards and advisory councils, including Redesign Health, Link-Age Launch, CareFi, and MultiplAI, where he contributes his vision and expertise. As a Fellow of the American College of Healthcare Executives (FACHE), he has also earned multiple certifications in healthcare management and employee benefits, underscoring his commitment to professional excellence.

A recognized thought leader, James has been featured in esteemed publications such as The Wall Street Journal, Forbes, and Managed Healthcare Executive for his insights on healthcare analytics and industry trends. He is also a contributing author to the 2019 CRC Press publication Healthcare Analytics: Foundations and Frontiers, further solidifying his reputation as an authority in the field.



Jane Suh

Mentor - Digital Health

Principal, AlleyCorp

Jane Suh is a Principal on the AlleyCorp Healthcare team and spends her time on incubation, identifying new investment opportunities, and supporting portfolio companies. She was previously a Partner at Andreessen Horowitz on the a16z Bio Fund, backing entrepreneurs at the intersection of healthcare, bio and tech. She was on the founding team of the Bio/Healthcare GTM Network group and advised portfolio companies on go-to-market strategy, business development, sales and product marketing.



Jesse Shefferman

Mentor - Life Sciences

CEO and Founder, Protara Therapeutics, Inc.

Jesse Shefferman is a co-founder of Protara and has led the Company since its inception through the addition of two late-stage assets, the establishment of multiple late-stage development programs and its listing on NASDAQ in early 2020. Jesse has spent over twenty years in the biopharma industry holding several strategic leadership and financial roles.

Prior to co-founding Protara, Jesse was Vice President and Head of Business Development at Retrophin Inc., a leading rare diseases company where Jesse was a member of the executive leadership team and executed a number of company-defining transactions. Prior to Retrophin, Jesse served as Director, Strategy and Business Development at Vertex Pharmaceuticals, Inc., where he focused on hepatology and rare disease programs. Jesse previously served as an investment banker with Barclays Capital and Lehman Brothers, where he focused on providing strategic and financial advice to the management teams and boards of directors of numerous biopharmaceutical companies.

Jesse holds an MBA and Certificate in Health Sector Management from Duke University and a BA in Accounting from Gordon College.



Jin Montclare

Scientific Mentor - Life Sciences

Professor, Chemical and Biomolecular Engineering, NYU Tandon

Jin Kim Montclare is a Professor in the Department of Chemical and Biomolecular Engineering at NYU Tandon School of Engineering. Her research is focused on groundbreaking research in engineering proteins to mimic nature; she works to customize artificial proteins with the aim of targeting human disorders, drug delivery and tissue regeneration as well as create nanomaterials for electronics.

Prior to joining NYU-Tandon, Montclare was a postdoctoral fellow at the California Institute of Technology in the Division of Chemistry and Chemical Engineering. She has won numerous awards throughout her career and is a member of the American Chemical Society, the International Society for Pharmaceutical Engineering, the Biophysical Society, the Materials Research Society, the Biochemical Society, the Protein Society and American Association of Cancer Research, and the American Institute of Chemical Engineers.

She received a Bachelor of Science in Chemistry from Fordham University in 1997, a Master of Science and a Ph.D. in Bioorganic Chemistry from Yale University in 2001 and 2003, respectively.



Jinsy Jacob

Mentor - Digital Health

Physician, Human+Machine rise

I am a physician and investor passionate about creating a better healthcare system for everyone. I currently work as a Pediatric ER physician and as a Venture Partner Human+Machine rise.



Jodd Readick

Mentor - Digital Tech, Digital Health

CTO, Precision Ag AI and IoT

Jodd has spent 30+ years as a serial entrepreneur, product innovator, and management consultant. He has designed and managed telecom infrastructure systems as an entrepreneur and Fortune 100 executive. He is co-founder of User Centric Communications, Vumber.com, and DMI Communications. Jodd is also the co-founder of Unwired Mobile, a patented blockchain technology for international mobile roaming, and CEO of LymeLog, a medical app for chronic Lyme patients. Previously, he spent five years at DuPont where he was one of the four founders of the business unit that created Rapid Prototyping which became Agile. He was the telecommunications subject matter expert for Arthur Anderson, advised Wells Fargo on call center architecture, and created the first expert system for medical billing for Beth Israel Hospital.

Jodd is an active angel investor and a founding member of the New York chapter of Keiretsu Forum, the world's largest angel network. He holds a BA in Psychology with an emphasis in Artificial Intelligence from Stony Brook University.



Jose Bohorquez

Mentor - Digital Health

President, Bold Type

Jose Bohorquez is founder and President of Bold Type, a firm specialized in developing secure, compliant medical device apps. At Bold Type, Jose leads a team of engineers and designers with expertise in firmware, mobile apps, cloud infrastructure, cybersecurity, and data analytics.

Dr. Bohorquez received his bachelor's and master's degrees from the University of Florida in electrical engineering and computer science. He completed a PhD in electrical engineering and computer science at MIT with a minor in business administration from the Sloan School of Management. At MIT, Dr. Bohorquez was awarded an MIT Presidential Fellowship and his research was selected for presentation as part of the MIT/MTL Doctoral Dissertation Seminar in 2009. His work at MIT resulted in more than a dozen peer-reviewed publications.

Since completing his doctoral studies, Jose has dedicated his career to technical entrepreneurship. He has raised millions of dollars in venture capital, launched several award-winning products, and generated tens of millions of dollars of revenue. He is a passionate advocate for innovation and enjoys mentoring new entrepreneurs and young engineers.



Josh Raysman

Mentor - Digital Health

Principal/Advisor, Negative Split - Digital Advisors

Josh, a former leader of Pfizer's Digital Innovation organization, now advises a range of healthcare clients looking to drive value from their investments in data, analytics, and artificial intelligence - leveraging both in-house capability development as well as novel partnerships across a rapidly changing digital ecosystem focused on healthcare.

Throughout prior roles, Josh has led teams focused on leveraging advances in AI and machine learning to create a healthier world. Most notably, the groups' have developed more than 20 digital companions that have supported 100,000s digital interactions with patients & healthcare providers. Broadly, these companions and other intelligent tools have been instrumental to driving customer, market, and patient insights that improve outcomes.



Keerthi Vishnudas

Mentor - Digital Health

Director, Partnerships & Innovation, GE Healthcare

Keerthi currently leads Partnerships and Innovation at GE Healthcare focused on digital and AI for the \$3 billion ultrasound franchise. Over the last 15 years, she has specialized in medical imaging and image guided cancer therapy in roles ranging from R&D, product management, product marketing and strategic partnership management. Development of KOL-based marketing, clinical evidence and reimbursement strategy to launch disruptive health-tech has been the focus of her time in industry. Throughout her career she has realized the power of strategic industry/academia partnerships to innovate and successfully launch disruptive health-tech. At GE Healthcare, Keerthi is now focused on building a co-innovation and commercialization framework with startups to accelerate digital/AI innovation and support the startup ecosystem by providing access to GEHC's commercial activation processes. She earned her PhD in biomedical engineering specializing in MRI system design and completed her post doctoral fellowship in radiology at the University of California, San Francisco.



Kevin Cho

Mentor - Life Sciences

Associate Director, CDO Sales Team, Samsung Biologics

Kevin currently is part of the US/EU business development team at Samsung Biologics. He started his career on the drug development side at Caladrius Biosciences (later acquired by Hitachi) focused on cell therapies. Afterwards, he shifted over to the investment sector focused on small-/micro-cap public biotechnology companies (Viking Therapeutics, Cardiff Oncology, Processa Pharmaceuticals, Jaguar Health). Prior to joining Samsung, he spent his time growing a Cold Spring Harbor Laboratory spin-out through its Series A funding in addition to forming multiple Big Pharma and large biotech partnerships.



KP (Suba) Subbalakshmi

Mentor - Digital Health

Professor, Stevens Institute of Technology

K.P. (Suba) Subbalakshmi is a Professor in the Department of Electrical and Computer Engineering at Stevens Institute of Technology. A distinguished Fellow of the National Academy of Inventors and a Jefferson Science Fellow, she actively contributes to the National Academy of Sciences, Engineering, and Medicine's Intelligence Science and Technology Experts Group (ISTEG).

Her research focuses on trustworthy Artificial Intelligence and Machine Learning, with applications in mental health, cybersecurity, and fintech. In 2016, she was appointed as a Jefferson Science Fellow, where she served as a senior science and technology advisor to the U.S. Department of State.

Suba has received the Innovator Award from the New Jersey Inventors Hall of Fame and serves as an Associate Editor for both the IEEE Transactions on AI and the IEEE Transactions on Neural Networks and Learning Systems. As a former co-founder of technology start-ups and a holder of several patents, she is dedicated to fostering innovation and guiding the next generation of entrepreneurs.



KK Kambhampati

Mentor - Deep Tech, Digital Tech, Digital Health

Partner, Cloquet Capital Partners

Krishnamurthy is a partner at Cloquet Capital Partners making early-stage technology investments. He is a visiting faculty at Cornell Tech in New York and a Member of the eCornell and External Education Advisory Board. He serves as an Independent Board Member as well as a hands-on mentor/advisor to several early-stage startups at several New York's leading accelerators and incubators. He co-founded uReach Technologies, Inc., a communications applications and services company, and served as its CEO, until its sale. Prior to founding uReach, he served in a variety of management and technical positions at AT&T Bell Laboratories. He holds a master's degree in computer science from Cornell University and a master's degree in mathematics from the Indian Institute of Technology in New Delhi.



Kristin King

Mentor - Digital Health, Deep Tech

Vice President, Corporate Development, M&A, Defibtech, LLC

Kristin King is an accomplished Biotech executive, serial intrapreneur, investor, and strategic advisor to startups developing biotech solutions. Kristin serves on Boston Harbor Angels Management team and an active Angel Investor. She is currently Vice President, Corporate Development, M&A at Defibtech, a Nihon Kohden company based in Guilford CT.

With over 25 years' leadership roles in corporate strategy, venture investment, commercial and technical development Kristin has championed healthcare innovation within both startups and Fortune 100 Global companies. She serves on Board of Directors for Boston ENET.

Kristin holds an MBA in Finance and Marketing from NYU Stern and a BS in bioengineering and mathematics from Syracuse. She is an avid scuba diver and environmental volunteer.



Lawrence Johnson

Mentor - Digital Health

Senior Vice President and Head of Fintech Engagement, Morningstar

Lawrence Johnson is Senior Vice President & Head of Fintech Engagement at Morningstar. Lawrence leads Morningstar's global financial technology outreach initiatives. He is working to strengthen the firm's leadership role fostering innovation in software, data management, business intelligence and user experience in the financial services sector.

Lawrence is a member of the Fintech Advisory Board of the Fubon Center for Technology, Business, and Innovation - NYU Stern School of Business, and the Board of Directors of iD-Lab. Lawrence has moderated and served on panels at London Fintech Week, Fintech Week Chicago, IBM Think 2018, CryptoCon 2018, and others. He has also led emerging growth companies to successful exits, including RightPond (acquired by Morningstar), a Fintech company using machine learning to harvest unstructured financial data. He was a co-founder of yellowpages.com (acquired by AT&T), and director of CLRS Technologies (acquired by Solta Medical - Valliant).

Before his entrepreneurial endeavors, Johnson practiced law in the area of securities and technology law. He began his career at IBM. He holds a commerce degree from McGill University and a law degree from the Université de Montréal. He is a member in good standing of the California Bar.



Lorraine Marchand

Mentor - Life Sciences, Deep Tech

General Manager, Life Sciences, Watson Health

Lorraine Marchand is a life sciences executive who can break down complex business problems and develop creative solutions strategically aligned with companies' financial goals and address stakeholders' needs. Lorraine has held executive roles in Management, Operations and Business Development for Bristol-Myers Squibb, Covance, Clinilabs and Cognizant Technology Solutions. She co-founded two life sciences companies and has led over 200 clinical programs from pre-clinical to NDA submission and launch. Lorraine developed a course on accelerating the commercialization of new technologies for Princeton University where she served as James Wei Visiting Professor of Entrepreneurship. She is adjunct professor and advisory board member, Columbia Business School. Lorraine has served on the Board of Advisors for Morood Inc., a private equity firm and on the steering committee for the Mid Atlantic Bio Angels. She is advisor to the University City Sciences Center, Philadelphia and the Columbia University Precision Medicine Initiative's Biotech Seminar Series.



Marc Weill

Mentor - Digital Tech, Digital Health

Senior Advisor, Two Sigma Ventures

Marc Weill is a Senior Advisor at Two Sigma Ventures where he provides strategic support to portfolio companies and helps source and evaluate investment opportunities. He has served as an investor at nearly every stop in his more than 25-year career, which includes serving as Chairman of City Light Capital Investment (2004 to 2008) and WST Partners (2001 to 2003). He was also Chief Investment Officer / SEVP of Citigroup from 1991 to 2000 where he led the Citigroup Investment department of 600 employees and \$130 billion in insurance, investment, pension fund, and wealth management business lines.



Mark Kolb

Mentor - Digital Health

Partner, Tech Council Ventures

Mark Kolb is a Partner at Tech Council Ventures. He is an entrepreneur turned venture capitalist focused on the health care industry. Before joining Tech Council Ventures, he was the CEO of Bergen Medical Products. Before that he was running BKHealth, where he and his partner were issued patents for a physical therapy robot and an exercise device. At Dynamic Clinical Systems, he joined as Board Chair transitioned to CEO, and then repositioned the company for a sale to Press Ganey. Earlier, he founded the life sciences consulting firm Taratec Development Corporation. He raised venture capital and led its considerable growth there before selling the company to Patni Computer Systems, one of India's largest IT firms. Serving then as a senior vice president at Patni, he led their global life science business. Along the way, Mark has consulted for early-stage technology companies, supporting them in planning, finance, operations, and fundraising. He has served on several corporate and non-profit boards, including Taratec, Dynamic Clinical Systems, Moda Technology, the Somerset Medical Center, and the NJ Technology Council. Mark currently serves on the boards of Mend, ReGelTec, Kuiper, Vitalief, Dorsata and Optima Global Services. Mark's personal and company awards include the E&Y NJ Entrepreneur of the Year and NJTC Growth Company of the Year. He earned his bachelor's degree in electrical engineering from the University of Notre Dame and attended the OPM program at Harvard Business School.



Maude Tessier

Mentor - Life Sciences

Chief Business Officer, Seismic Therapeutic

Maude Tessier is a versatile senior executive, company builder, and deal maker who thrives at the interface of science and business in research & development stage companies focused in oncology and immunology. Maude is a 2-time CBO with 16+ years of BD & corporate strategy, and cross functional business experience in public and private biotech, pharma, and academia. As CBO of Ikena (Nasdaq: IKNA), she led the negotiation of \$1B+ partnership with BMS, company rebranding and pipeline expansion into targeted oncology, the acquisition of Amplify Medicines, and, as member of the executive team, financing activities resulting in >\$260M in private and public capital. Maude is also trained as a cancer biologist.



Melissa Moore

Mentor - Life Sciences

Vice President of Clinical Research, Plus Therapeutics, Inc.

Dr. Moore has over fifteen years of experience in oncology, molecular diagnostics, and radiotherapeutic drug development. Her corporate roles include start-up leadership experience, full lifecycle product development, funding and capitalization, manufacturing, and regulatory strategy. Prior to joining Plus Therapeutics where she is the VP of Clinical Research and Development, she was a co-founder of SOFIE and served as its Chief Technology Officer. While at Sofie, she was specifically responsible for leading the Clinical Development Program, Radiopharmaceutical Contract Manufacturing Operations, and the Quality Assurance/Regulatory Affairs Division. Dr. Moore has also led Development at the Damon Runyon Cancer Research Foundation in New York. Previously, she was a Visiting Scientist at University of California, Los Angeles and principal investigator on numerous governmental grants and contracts. Additionally, she sits on various related scientific review boards for the National Institute of Health. Dr. Moore received her Bachelor of Science degree from University of California, Berkeley and her PhD from University of California, Los Angeles, where she also completed her post-doctorate research in Molecular and Medical Pharmacology.



Merika Koday

Mentor - Life Sciences

Principal, Accelerator Life Science Partners

Merika Koday, PhD, currently serves as a Principal for Accelerator where she is responsible for sourcing and evaluating emerging biotechnology investment opportunities. Merika also provides project management and scientific development oversight to select Accelerator portfolio companies, including Automera and KayoThera. She currently serves on the Board of Directors for KayoThera and Life Science Washington. Before joining Accelerator in 2018, Merika served as project manager for Cell and Gene Therapy at Seattle Children's Research Institute. She helped advance basic research programs into clinical development and supported industry partnerships and collaborations. Previously, Merika was a co-founder and Senior Scientist at Virvio, a University of Washington spin-out company focused on developing de novo designed proteins as therapeutic alternatives to monoclonal antibodies. Merika received her Ph.D. from the University of Washington and a B.S. from the Colorado School of Mines.



Miriam Bredella

Mentor - Digital Health

Associate Dean for Translational Science, Grossman School of Medicine
Director, Clinical and Translational Science Institute, Professor of Radiology

Dr. Bredella is Associate Dean for Translational Science and Director of the Clinical and Translational Science Institute at NYU Langone Health and Grossman School of Medicine. She is also a musculoskeletal radiologist and professor of radiology and vice chair for strategy in the Department of Radiology at NYU. She holds an MBA from MIT/Sloan School of Management. <>>Dr. Bredella is an NIH-funded physician scientist focusing on novel functional imaging techniques to determine the effects of different fat depots on bone and metabolic risk across the weight spectrum and in patients with cancer. Recently she has worked on implementing opportunistic screening (using CT scans performed for other purposes to assess bone and cardiovascular health) into clinical practice. Dr. Bredella has been continuously grant-funded as PI by the NIH and has been elected to be a member of the NIH Clinical and Translational Science Awards (CTSA) Program Steering Committee and chairs several national CTSA working groups on workforce development. She is the author of 300 peer-reviewed manuscripts and multiple textbooks. She is a fellow of the American College of Radiology and a Scholar in Diagnostic Excellence of the National Academy of Medicine. She is the recipient of multiple awards, including the Distinguished Investigator Award from the Academy of Radiology Research and the Presidents Medal of the International Skeletal Society.



Mirza Ahmed

Mentor - Digital Health

Senior Director, Digital Healthcare, Business Operations, Hikma Pharmaceuticals

Mirza Ahmed is a Partner at Bridge-ME, a firm focused on bridging foreign start-ups to the Middle East and North Africa. He specializes in commercial growth and data strategy with an industry focus in PharmTech. Previously, he was a Senior Director at Hikma Pharmaceuticals where he led the company's HealthTech-related portfolio growth efforts, including their Corporate Venture Capital team. Mirza successfully expanded Hikma Ventures' portfolio of companies with a focus on digital therapeutics including partnerships in the MENA region. Prior to Hikma, he was a technology strategy leader for Syneos Health's commercial businesses and a management consultant with PwC. Mirza currently also serves as a Partner with Bacchus Venture Capital, HealthTech advisor to OCA Ventures, and has past experiences with the United Nations and Council on Foreign Relations.



Monica Cheng

Mentor - Life Sciences

Senior Director of Business Development, The Janssen Pharmaceutical Companies of Johnson&Johnson

Monica Cheng is Director of Business Development & Licensing (BD&L) for Cardiometabolic Diseases at Boehringer Ingelheim (BI). Her responsibilities include development and implementation of partnering strategy and support of all partnering activities related to the Cardiometabolic therapeutic area. Additionally, Monica leads the effort in increasing BI's footprint in NYC through BI's mentoring initiatives such as BI Office Hours and BI Academy to foster the local life science community. She has also mentored numerous life science startups through MassConnect and NIH's SBIR program. Prior to joining BD, Monica was head of a research lab within BI's Cardiovascular Research organization. She received her Ph.D. in Pharmacology from New York Medical College and her BS in Microbiology from University of Minnesota.



Nadav Shimoni

Mentor - Digital Health

Managing Director , Arkin Digital Health

Dr. Nadav Shimoni serves as Managing Director at Arkin Digital Health, an early stage VC operating under Arkin Capital, funding and supporting entrepreneurs harnessing software to address unmet business needs in healthcare.

In this role, Nadav oversees a spectrum of investment activities, including deal sourcing, due diligence processes, and ongoing support for portfolio companies. He serves on the board of Laguna, Rhino, Edocate, Medminder, Eleos, Validic and Siftwell.

Dr. Shimoni is a physician by training. Prior to Arkin, he served as the Director of Hospital Business Development at Clalit Health Services (Israel's largest HMO, providing care and coverage for 4.5M members), Head of Business Development at Rambam Medical Center, and Associate at Accelmed, a VC and PE firm specializing in medical device investments. In parallel, he conducted public health research focused on the implementation of data and AI-driven solutions in clinical workflows.

Dr. Shimoni holds an M.D. from Ben-Gurion University, graduating magna cum laude.



Nancy Ondovik

Mentor - Life Sciences

Principal, New Company Creation JJDC, Johnson & Johnson

Experienced business development professional with 20+ years of progressive responsibility in new product development, valuation, deal making, and alliance management. Verifiable track record of managing complex negotiations and leading cross-functional deal teams to successful execution of business transactions in competitive deal processes.

As a member of JJDC, I am now focused on developing new growth platforms for each of Johnson & Johnson's business sectors through the creation of innovative start-up companies which are focused on addressing unmet needs, accelerating innovation, and making a difference for healthcare providers and patients around the world.



Navneet Puri

Mentor - Life Sciences

Founder & Board Member, Nevakar, Inc.

Dr. Puri is a pharmaceutical scientist by education with over 25 years of life science industry experience.

He founded Nevakar, Inc. in 2015 with a vision of improving patients' quality of life and healthcare outcomes in hospital and ophthalmology segments. Nevakar was further split into two separate companies, including Nevakar Injectables Inc and Vyluma Inc.

Prior to Nevakar, Dr Puri spent several years in product development and drug delivery of parenteral pharmaceuticals at Baxter Healthcare Corp. and Amgen Inc. He founded InnoPharma, Inc. in 2005, focusing on development of hospital injectable products. Following the acquisition of InnoPharma by Pfizer in 2014, he stayed on as Vice President of Pfizer's Worldwide Research & Development and President of InnoPharma until 2015.

Dr. Puri received Future 50 magazine's Smart CEO award in 2015. He was also awarded the EY Entrepreneur of The Year award from the state of NJ in 2015.

Dr Puri's past board positions include InnoPharma, Eyenuk, Xeris Pharmaceuticals and BioNJ. His current board positions include Nevakar, Alzeca Biosciences, [Chair] Rutgers Health Leadership Council, [Advisory Board] TiE NJ, and [Advisory Board] New Jersey Economic Development Authority.

Dr. Puri earned a BS in Pharmacy from University Institute of Pharmaceutical Sciences (India), MS from the University of Mississippi and a PhD in Pharmaceutics from Rutgers University.



Nil Gural

Senior Associate, Polaris Partners

Mentor - Life Sciences

Nil joined Polaris in 2022 where she focuses on biotech and healthcare investments. Prior to joining Polaris, she was a manager at Bain & Company's healthcare practice with a focus on pharma and medical devices. Before Bain, she was a part of the initial team at Glympse Bio where she helped develop their platform technology. Nil holds a PhD from the HST program of Harvard & MIT where she was an HHMI fellow and a BS in Biomedical Engineering from Washington University in St. Louis.



Nimit Mehta

Partner, Bain & Company

Mentor - Digital Tech, Digital Health

Nimit has 20 years of experience as an operator, leader, and consulting advisor in B2B Pricing, Marketing, R&D, and Corporate Strategy. He has advised many Fortune 1000 clients with pricing strategy, optimized price setting, sales enablement to improve pricing outcomes, and margin improvements through data-driven guidance, process optimization, and operating model redesign. His client portfolio encompasses numerous industries, including Healthcare, Chemicals, Advanced Manufacturing, Distribution, and Private Equity.

Before joining Bain, Nimit held various leadership roles in large corporations. Most recently, he was the head of marketing and sustainability for BASF, where he led successful product launches, customer growth strategies, and portfolio pricing. He also established and led a pricing center of excellence (CoE), where his team enabled many business units to achieve significant EBIT improvement through pricing excellence capability building. Nimit also led strategic pricing for national accounts and R&D in a medical device leader Boston Scientific.

He holds an MBA from the University of Minnesota, an M.S. in Computer Science, and a B.E. in Chemical Engineering.



Noam Solomon

CEO, Immunai

Mentor - Life Sciences

Noam Solomon is the CEO and co-founder at Immunai, the first company set to reprogram the immune system for better detection, diagnosis, and treatment of disease, and discovery of novel therapeutics.

Prior to co-founding Immunai, Noam had a dual career in both the industry and academia. Noam has a double Ph.D., in Math and Computer Science and served as a post-doctoral researcher in the Mathematics department at the Massachusetts Institute of Technology, and in the Center of Mathematical Sciences and Applications at Harvard University.

Noam also worked as an algorithms developer and a data scientist, consultant, and head of data science in several hi-tech companies in Israel.



Peter Alff

Senior Venture Partner, Orange Grove Bio

Mentor - Life Sciences

Peter Alff is a Senior Venture Partner at Orange Grove Bio based in New York City and brings nearly two decades of experience in biomedical science, startup operations, and venture capital investments to the EFL mentor network. Prior to joining Orange Grove Bio, Peter was Vice President of Partnerships at Owkin where he led partnership efforts in the US. Previously, he was an Executive in Residence with Kairos Ventures where he focused on Seed and Series A therapeutics investments and worked closely with scientists from top research universities to launch and manage numerous biotechnology companies as start-up CEO. Peter is also a former Business Development Manager for NYU's Office of Therapeutics Alliances, and he is a cofounder of Calder Biosciences, a protein-engineering and vaccine platform company, where he managed preclinical immunogen design and was Director of Strategic Initiatives.



Peter Pfeiffer

Senior Partner, McKinsey & Company

Mentor - Life Sciences

Peter leads in McKinsey's Global Biopharmaceuticals Practice and was former head of the New Jersey office. Over his McKinsey career, Peter has helped leading companies in the pharmaceutical and medical products industries achieve their goals and stay competitive, having served clients in the US, Europe, Japan, and China. He currently leads the Firm's biopharma advanced analytics (Quantum Black) team in North America. Peter partners with biopharmaceutical companies to tackle challenges like developing company- and business-unit-level strategies, optimizing portfolios, assessing and executing M&A transactions, and undertaking value-capture initiatives. Formerly leading our Clinical Development Practice, Peter also understands R&D, medical and related functions. In addition to serving large cap multi-national healthcare companies, Peter has supported biotech companies (small and mid-cap) on its growth journey, including portfolio strategy, business development, functional excellence, commercialization and xUS market entry Initiatives. Peter has also supported various industry collaborations and associations, including BIO, DIA, and CPath.



Priyanka Rohatgi

Entrepreneurial Business Leader, Venture Capital, Pharmaceutical, and Biotechnology

Mentor - Life Sciences

Priyanka Rohatgi is an entrepreneurial business leader with over 15 years of experience in venture capital, pharmaceutical, and biotechnology. She leverages her deep expertise in venture capital, business development, and scientific research and collaborates with entrepreneurs in Biotech companies as their fractional CBO and business advisor.

Previously, she was a Partner at Novo Ventures, Longwood Fund, Ipsen Ventures, AbbVie Ventures, and Baxter Ventures. Priyanka also served as a board member/observer for several biotech companies, including Artios Pharma, Jnana (acquired by Otsuka), Interius BioTherapeutics, Mirna (NASDAQ: MIRN), Naurex (acquired by Allergan), Precision Bioscience (NASDAQ: DTIL), Pyxis Oncology (NASDAQ: PYXS), Sanifit (acquired by Vifor Pharma), Syntimmune (acquired by Alexion), and Xilio Therapeutics (NASDAQ: XLO).

Priyanka holds a Doctorate and Master's in Pharmaceuticals, Biochemistry, and Computational Biology from the University of Washington, Georgia Institute of Technology.



Rachael-Linn Spooner

VP Strategic Planning, Clinical Digital Solutions, Northwell Health

Mentor - Life Sciences, Digital Tech, Digital Health

Rachael currently serves as the Vice President of Strategic Planning in Clinical Digital Solutions at Northwell Health. Her career has focused on leveraging her expertise in defining strategy, developing new programs, and optimizing organizational processes through integration of novel tools and techniques to transform clinical care delivery. Prior to Northwell, she spent time in healthcare strategy consulting. Rachael is a proud graduate of the NYU Stern School of Business and Fellow of the American College of Healthcare Executives.



Rahul Mehendale

CEO | Health Tech

Mentor - Digital Health

Rahul Mehendale is a seasoned executive with a background in leadership and strategic management, currently serving as the CEO at a stealth health tech startup and advisor to various AI and Data Analytic ventures. He has a rich track record of driving disruptive growth and innovation within the healthcare sector. Previously, Rahul held significant roles at various organizations, including serving as Managing Director at Deloitte leading their Future of Health business efforts, and CEO of mySkin Inc. a healthcare technology company that created the quantified skin category. His career is marked by a strong focus on leveraging technology like AI, Data and Analytics, AR-VR technologies to improve healthcare outcomes. Rahul graduated with an MBA from Harvard Business School, an MS from the University of Wisconsin-Madison and a BE from the University of Pune. Rahul is an health and fitness fanatic and can be seen taking long walks along the NYC waterfront with his wife, Aarti, and their two daughters.



Rick Peng

Mentor - Digital Health

Digital Health Innovation, Business Development, Licensing, MSKCC

Engineer/MBA with healthcare experience across pharma (Merck - R&D), health technology (Flatiron Health - EMRs and RWD), and health system/providers (MSKCC - oncology-focused academic medical center). Functional expertise ranging from innovation management, product development / commercialization, partnership and BD/transactions, operational excellence including technical operations.



Roger D. Klein, MD JD

Mentor - Life Sciences, Digital Tech, Digital Health

Principal, Roger D. Klein, MD JD

Roger D. Klein, MD JD is a board-certified molecular pathologist who was formerly Chief Medical Officer of OmniSeq, Inc., a tumor profiling company that was sold to LabCorp. He has served as medical director of molecular oncology and at several academic institutions, most recently Cleveland Clinic. In addition, he has served as a medical, strategic, and regulatory consultant in the biotechnology, clinical laboratory, diagnostics, and medical devices industries. A leading figure in the field, Dr. Klein has advised the Departments of Health & Human Services, Food and Drug Administration, the Centers for Medicare & Medicaid Services, and the Centers for Disease Control and Prevention, and held leadership roles on and participated in numerous professional society committees at the Association for Molecular Pathology, the College of American Pathologists, the American Society of Clinical Oncology, the Clinical Laboratory Standards Institute, and the American Medical Association. Dr. Klein has over 50 peer-reviewed articles and book chapters. He completed medical school and internship at Case Western Reserve Medical School, residency and fellowships at Yale Medical School, and a fellowship at Mayo Clinic. He earned his law degree at Yale Law School. He is licensed to practice medicine in New York, Ohio, and Florida, licensed to practice law in the District of Columbia, Ohio and member of the United States Supreme Court Bar.



Roland Turck

Mentor - Life Sciences, Digital Tech, Digital Health

Managing Partner, TurckBio

Dr. Roland Turck is a Managing Partner at TurckBio, a specialty medicine-focused strategy advisory firm for biotech investors, boards, and executive teams. Roland has more than 25 years of executive experience in the biopharm industry. Prior roles include President & COO of Formula Pharmaceuticals, an oncology start-up he co-founded, President of Global Specialty Medicine at Bayer, and President of Bayer Schering Pharma for Latin America and Canada. Roland is also a GP in a pre-seed venture fund and co-chairs a NY-based angel network.



Ron Cohen

Mentor - Life Sciences

Biopharma Consultant

Ron Cohen, M.D. served from 1994-2024 as Founder, President and CEO of Acorda Therapeutics, Inc., a public biotechnology company that developed therapies for disorders of the nervous system, including approved and commercialized therapies for Parkinson's disease and Multiple Sclerosis. Dr. Cohen previously was an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses.

Dr. Cohen is past Chair of the Board of BIO, of BIO's Emerging Companies Section, and of the New York Biotechnology Association (NYBIO). He is a recipient of Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and of the NY CEO Lifetime Achievement Award. Dr. Cohen received his B.A. degree in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine.



Ron Lennox

Mentor - Life Sciences, Digital Health

Board Member, RadImmune Therapeutics and Thetis Pharmaceuticals

Ron has been an active investor in early stage life sciences companies for over twenty years. He has served on the boards of over 18 companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson, Inc.) and Applied Molecular Evolution, Inc. (acquired by Eli Lilly Corp.). He has been involved in the founding of seven companies, six of which were successful. He was the founding CEO and Chairman of Protometrix, Inc. (acquired by Life Technologies, Inc.) and also of CGI Pharmaceuticals, Inc. (acquired by Gilead Sciences, Inc.). In addition, he was founding Chairman of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and a founder who served as Executive Chairman of Bikam Pharmaceuticals, Inc., engineering the sale of the company to Shire Pharmaceuticals PLC in July 2014. He has also helped found polyGenomics, Inc., American Renal Associates, Inc., and Biorelix, Inc. 11 additional companies he led investments in had successful IPOs, including i-STAT Corp, British Biotechnology, Ltd and Threshold Pharmaceuticals, Inc.

Ron began his venture capital career with Hancock Venture Partners (now HarbourVest Partners). He was a Founding Partner at CHL Medical Partners which raised three successive funds from institutional investors. He is a Mount Sinai Innovation Partner and serves on the board of Octagon Therapeutics, Inc., and is an advisor to several privately held biotechnology companies.

Ron has a B.Sc. in Molecular Biology from the University of Glasgow, a D.Phil. in Cell Biology from Oxford University and an MBA from The Wharton School of the University of Pennsylvania. He lives in New York's Greenwich Village with his wife and daughter.



Sahil Kirpekar

Mentor - Life Sciences, Digital Health

Chief Business Officer, atai Life Sciences, Angel Investor, Startup Mentor, Board Director

Sahil Kirpekar, MD is the Chief Business Officer at atai Life Sciences (NASDAQ: ATAI), a company that was created with the vision of leveraging innovation in mental health, including psychedelics to bring novel treatments to patients in neuropsychiatry. In this role, Dr. Kirpekar leads portfolio strategy, capital allocation, internal and external investments, as well as the early commercial development of atai's pipeline. Beyond his work at atai, he is also an active angel investor, startup mentor, and board director, contributing his expertise to the broader entrepreneurial and healthcare ecosystem.

Dr. Kirpekar joined atai in 2022, following over eight years at Otsuka Pharmaceutical Co., Ltd., where he held the position of Head of Business Development and Co-Chair of the Global Business Development Committee. He orchestrated several high-profile deals valuing over \$2.7 billion and played a pivotal role in launching two major drugs—Abilify Maintena (Aripiprazole) and Jinarc (Tolvaptan)—while shaping early pipeline strategies and advancing digital health tools. Additionally, he founded a company that developed a novel drug delivery device to address adherence challenges, and he has collaborated with the World Health Organization.

Dr. Kirpekar is a trained physician and holds an MPhil from the University of Cambridge (where he is subsequently an honorary lecturer).



Sapna Srivastava

Mentor - Life Sciences

Director, Independent

Dr. Srivastava has almost 25 years of experience in the biotechnology industry, encompassing independent director and senior executive roles in the biopharmaceutical companies, and as a senior biotechnology analyst on Wall Street.



Sarah Dolman

Partner, Recon Strategy

Mentor - Life Sciences

Sarah is a Partner at Recon Strategy, focused on science and technology innovations in life sciences and healthcare. Previously, she was a member of the Strategy team at Verily Life Sciences, where she developed product roadmaps and commercial launch plans for multiple programs. Sarah's work in strategy began at the Boston Consulting Group, where she supported biopharma & med-tech clients in prioritizing R&D programs and improving supply-chain operations. Prior to BCG, Sarah was a Director at Merck, where she led teams in Process Research designing innovative technical solutions to complex synthetic and scale-up challenges for clinical and commercial drug supply.

Sarah has a PhD in Organic Chemistry from MIT, an MBA from NYU-Stern, and an Hon-BSc from the University of Toronto.

Sean Day

Venture Principal, Rock Health Capital

Mentor - Digital Health

Sean is a Principal Investor at Rock Health Capital, an early-stage digital health venture fund. He previously led market research at Rock Health Advisory, advising enterprise healthcare companies on their digital strategies. Sean started his career in product at Epic, and he holds a bioengineering degree from Union College and a masters degree in technology policy from the University of Cambridge. Sean is a former Watson Fellow, having spent a year studying mobility technology across different cultures in Ethiopia, India, and Japan.



Sean Schreiber

EVP/COO, Alliance Health

Mentor - Digital Health

Sean currently serves as the Chief Operating Officer at Alliance Health, a Medicaid managed care entity. He previously served as the company's Chief Clinical Officer at its inception. Sean has extensive experience developing, implementing and operating new programs and services both on the health plan and service delivery side. He has served as a consultant and development director scale behavioral health services.



Sejal Patel

VP Chemistry, Scorpion Therapeutics

Mentor - Life Sciences

A data driven scientific leader, Sejal is a problem solver at heart, and not afraid to challenge the status-quo. She has enabled novel drug discovery programs from start to finish, across multiple disease areas. She has experience in drug delivery technologies, digital therapeutics, academic collaborations, and strategic partnerships. She has been a long-standing advocate of mentorship programs, and to level up inclusivity in the sciences.

Education and experiences:

Scorpion Therapeutics

Novartis Institute for Biomedical Research

Kosan Biosciences

UC Irvine and MIT



Ser-Chen Fu

Partner, Pacific 8 Ventures

Mentor - Life Sciences

Dr. Ser-Chen Fu was previously trained as a clinical neurologist and served as an attending physician during his clinical practice. At Pacific 8 Ventures, he provides a clinical and medical perspective in assisting healthcare startups realize their visions. Dr. Fu is passionate about helping healthcare related startups, and believes the success of startups will determine the future of healthcare and medicine.



Serhat Pala

General Partner, Cross Ocean Ventures; President, NuFund Ventures

Mentor - Digital Tech, Digital Health

Serhat Pala is a partner and co-founder of Cross Ocean Ventures, a founder focused venture capital firm that funds and mentors European startups expand to the US market. Before COV, Serhat Pala was a serial entrepreneur who started and grew numerous high-growth technology companies in e-commerce, SaaS, diagnostics, and digital health. The last company Serhat co-founded, Confirm BioSciences, a national provider of point-of-care employee screening and wellness testing, was acquired in 2020.

Serhat has more than 25 years of experience in technology commercialization, strategic business development, product development, change management, and growing early-stage companies with creative resourcefulness and scalable infrastructure.

Throughout his entrepreneurial endeavors, companies co-founded by Serhat have won numerous awards, including Inc 5000 (7x), Best Places to Work (4x), and International Commercial Leadership Award. Serhat is passionate about giving back to the community, educating future entrepreneurs, and diversity in entrepreneurship. Serhat and his wife, Zeynep Ilgaz, recently established the Ilgaz- Pala Family SDSU-Aztec Cooperative Fund Endowment to support aspiring student entrepreneurs in SDSU. In addition, Serhat currently serves on the board of several early-stage technology companies and non-profit organizations.

Serhat is originally from Izmir, Turkey, moved to the US for his MBA at SDSU and called San Diego home with his wife of 25 years, two boys, and three dogs. Serhat is a published author with a book about entrepreneurship, an inventor with several patents, and a former columnist for Inc magazine.



Shoibal Datta

Head of Digital Health Sciences, Takeda Pharmaceuticals

Mentor - Life Sciences, Digital Health

Shoibal Datta is Head, Digital Health Sciences within the Data Sciences Institute at Takeda. His team focuses on the incorporation of digital health technologies within clinical development specializing in decentralization of clinical trials, remote sensing and measurement and the development of digital health products for post-launch use. Prior to Takeda he was Vice President of PPD Digital where he set the strategy of working with external platform partners and device manufacturers to create compliant, globally scalable approaches to conduct decentralized trials and their integration into conventional clinical research and data management processes. Prior to that, he spent 13 years at Biogen in roles within translational informatics, data sciences and as part of an innovation hub that launched MS PATHS, a learning healthcare system that utilizes technology to capture high quality data as standard of care for over 10,000 MS patients globally supporting RWE and value-based medicine initiatives.



Silvia Garcia Codony

Associate Vice President, NY Ventures

Mentor - Life Sciences

Silvia is a venture investor, entrepreneur, and life sciences executive with over 20 years of experience in medical devices, biotech and digital health. Silvia is passionate about innovation and entrepreneurship being an active mentor and speaker at accelerators and events. Before becoming a venture investor, she co-founded a company in digital health helping people recover from trauma. Silvia held several leadership and consultant roles in the industry, including biotech, medical device and digital health companies across therapeutic areas such as cardiology, urology, plastic surgery, and diabetes among others.

Silvia started her career in Europe and moved to the States years to build the US affiliate for a European medical device company. She has worked in sales and business development, has a technical background in clinical and regulatory affairs and holds an MSc in Mathematics and an MBA from IE business school.



Sonal Matai

Mentor - Digital Health

Managing Director & President - US Business, Karl Storz United States

Sonal currently is the Managing Director & President - US Business, Karl Storz United States, where he leads a team of 2700+ dedicated employees across research and development, manufacturing, and commercial operations. In this position he is responsible for the overall operations of Karl Storz US and the associated profit and loss performance. He is active in developing corporate strategies to continue achieving profitability, business growth and increase market share for Karl Storz through the introduction of state-of-the-art technologies, innovative solutions and harnessing the capabilities of the human capital at Karl Storz.

Sonal was previously Managing Director, KARL STORZ Endoscopy-America, Inc. the commercial operations arm for Karl Storz in the US and led a team of 1600+ employees where he spearheaded a period of significant innovation and market share expansion.

Sonal has a diverse background of competing in global markets across Medical Devices, Consumer health and B2C business environments. Over the past two plus decades, he has worked in senior commercial, marketing and strategy positions at Karl Storz, Philips, and GE across the world in the USA, Netherlands, Switzerland, Thailand, and India.

Prior to joining KARL STORZ, Sonal had a short stint as CEO, Onera Health (Series B sleep diagnostics start up) based in Eindhoven, Netherlands.

Sonal has also served as the North American Business Leader for Philips' Sleep and Respiratory Care business. He successfully led the \$1.3 billion enterprise with 700+ FTEs through the COVID pandemic, meeting the surge in demand for ventilation and oxygen solutions, and transitioned the business to a more service-oriented model. Sonal is currently on the Board of Directors of California Life Sciences, and in the past has served on the Board of Directors for Respiroics Inc. and Council for Quality Respiratory Care (CQRC). Sonal is passionate about solving problems and delivering patient care across the health continuum in myriad care settings and making a measurable difference in patient outcomes.

Sonal grew up in India and Nigeria and holds dual citizenship (American and Dutch). He holds an MBA degree from IMD, Lausanne, Switzerland, and a Master's in Philosophy and a Master's in Economics from the University of Pune, India.



Steffanie Bristol

Mentor - Life Sciences, Digital Health

Advisor, Strategic Investor

Steff is a recognized leader and advisor in digital, data science, and technology innovation in healthcare across global life sciences, medical devices, and health system sectors.

Most recently, Steff was the Digital Health External Innovation Head of Strategy and Innovation at Biogen. In this role, she prioritized new digital and data science programs, led digital partnership business development, fostered ecosystem relationships, and oversaw strategic digital investments. Steff joined Biogen as the Digital Health External Innovation Head of Imaging and AI, where she led external innovation engagement and strategy for Imaging and AI opportunities.

Prior to Biogen, Steff held global strategy, business development, partnerships, and operational leadership roles at Philips. She joined Philips from Accenture Strategy, where she led consulting engagements focused on the healthcare and life sciences sectors. Steff has spent her career in health care including positions at Medtronic, Health Care Service Corporation, the Harvard School of Public Health, and Massachusetts General Hospital. Her experience includes corporate strategy, strategic alliances, business development, general management, commercialization, innovation model development, health policy, health services research, and program evaluation.

Steff is driven by improving human health at scale. In her free time, she enjoys spending time experiencing different cultures, learning about new cuisines and wines, and enjoying the outdoors. Steff has a B.S. in Health Science from Clemson University and M.B.A. and M.P.H. from the University of Michigan.



Stephen Chang

Strategic Partner, Cell One Partners

Mentor - Life Sciences

Dr. Stephen Chang has dedicated over three and half decades to pushing the boundaries of scientific innovation and bringing breakthrough treatments to patients in need. Through his leadership, Stephen has successfully navigated the complexities of drug development and commercialization, with a focus on cutting-edge technologies such as gene therapy, mRNA vaccine development, stem cell technologies and complex biologicals.

Stephen record of accomplishment speaks for itself, with two recent drug successes that have made a significant impact in the field of medicine. Adstilirin TM- rAd-*ifn*/ *syn3*, approved in December 2022 for bladder cancer therapy using gene therapy, and Intravail TMdiazepam, approved for epilepsy treatment through novel drug delivery. These are just a few examples of the groundbreaking work that has come out of Stephen laboratory or through his direct involvement.

Stephen experience as a researcher, entrepreneur, teacher, and scientific and business leader has equipped him with the skills necessary to navigate the challenges of the life sciences industry and bring transformative therapies to market. Stephen is a firm believer in the power of teamwork and diversity. Through his career of collaboration and access to different patient and stakeholder perspectives that we can truly drive innovation and make a difference in the lives of patients.

Stephen is a recognized pioneer in commercial gene therapy technologies and induced pluripotent stem cells, he is well-versed in the intricacies of drug development and have a proven record of accomplishment of success. He is also adept at navigating the political landscape and effectively communicating complex scientific concepts to a wide range of audiences.

In summary, Stephen passion for biotechnology and driving scientific innovation, coupled with my experience in drug development and commercialization, make me an asset in the life sciences industry. He looks forward to continuing to push the boundaries of what is possible in the field of medicine and making a lasting impact on the lives of patients around the world

Stephen graduated from Michigan with BS in four scientific disciplines, a Phd from University of California, Irvine in Biological Chemistry. Currently Stephen is on the Boards of private companies Mirimus, Virtus and Diodem. He is slated to join an upcoming IPO company as an independent director.



Vamsi Velcheti

Professor of Medicine, New York University | Hematology, Oncology

Mentor - Life Sciences, Digital Health

With over a decade of experience in medical oncology and drug development, I am a Professor of Medicine and a Director of the Thoracic Oncology Program at New York University. I lead a multidisciplinary team of researchers, clinicians, and educators who are dedicated to advancing the science and developing novel approaches to cancer treatment. I have a dual degree in medicine and business administration, and I have advanced training in drug and medical device development and operational and change leadership. I have multiple publications, patents, and awards in the field of cancer research, and I have extensive experience in conducting clinical trials, developing novel therapies, and collaborating with industry partners. I am passionate about teaching and mentoring the next generation of oncologists and innovators, and I strive to create a culture of excellence, diversity, and collaboration in my program. I am looking for opportunities to expand my network, share my insights, and learn from other experts in the field of oncology.



Victoria Gammerman

Mentor - Life Sciences, Digital Health

Global Head of Data Governance and Insights, Boehringer-Ingelheim Pharmaceuticals

I am passionate about improving healthcare by connecting the dots among patient-centricity, digital health, and real-world evidence to evolve clinical research through innovation and digital transformation.

In my current role as Global Head of Data Governance and Insights, I am accountable for shaping the data strategy and data governance for Clinical Development and Operations. Previously, I was the Head of Health Informatics and Analytics where I established the strategic priorities and led a team of data scientists who executed use cases to generate evidence from external clinical data and real-world health care data in support of drug development.

I have formal training with a PhD and MS in Biostatistics from the University of Pennsylvania School of Medicine and MA/BA in Mathematics from Boston University. I am also trained in Scrum/Agile methodologies (Product Owner and Scrum Master) as well as Design Thinking. I occasionally teach in the Applied Analytics program as an Adjunct Scholar-Professional Lecturer at Columbia University on Strategy & Analytics as well as Research Design.

I enjoy connecting with others who support the use of data to generate insights, especially with innovative applications to advance the health of patients!



Yizhen Dong

Mentor - Life Sciences, Digital Health

Partner, Global Founders Capital

Yizhen is a Partner at Global Founders Capital where he leads early stage investments in the frontier of bio, including AI in healthcare innovations, computational biology, synthetic biology, neurotech, medical robotics, and life sciences software. Prior to GFC, Yizhen was a Principal at 11.2 Capital where he led investments in computational biology and synthetic biology. Prior to 11.2 Capital, Yizhen helped launch Avastin in two cancer indications and developed marketing strategies across the product portfolio at Roche/Genentech. Yizhen was formerly a management consultant at ZS Associates after being a trained sushi chef for 7 years. Yizhen graduated magna cum laude in Economics from Vanderbilt University and received his MBA from The University of Chicago Booth School of Business.